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Cinacalcet HCl: A novel treatment for secondary hyperparathy-
roidism in stage 5 chronic kidney disease.
Background. Chronic kidney disease (CKD) alters the reg-
ulation of calcium and phosphate homeostasis, leading to sec-
ondary hyperparathyroidism, metabolic bone disease, soft tis-
sue calcifications, and other metabolic derangements that have
a significant impact on morbidity and mortality. The parathyroid
gland is the central organ responsible for regulating these adap-
tive responses. Suppression of parathyroid hormone (PTH)
secretion, hypertrophy, and hyperplasia are a major goal of
treatment of CKD.
Methods. Current literature was reviewed and combined with
the author’s experience to address a number of issues regard-
ing the optimal treatment of secondary hyperparathyroidism in
hemodialysis patients.
Results. The calcium sensing receptor (CASR) is the most
important factor regulating parathyroid gland function, and al-
losteric modulators of CASR, called calcimimetics, provide a
novel drug therapy to suppress PTH secretion. The current use
of active vitamin D analogues to suppress PTH is often lim-
ited by hypercalcemia and hyperphosphatemia. Clinical trials of
cinacalcet HCl, the first calcimimetic to be approved for treat-
ment of secondary hyperparathyroidism in CKD, have demon-
strated suppression of circulating PTH levels without incre-
ments in the calcium-phosphorus (Ca × P) product, making it
easier to achieve the stringent management guidelines proposed
for subjects with CKD by the National Kidney Foundation Kid-
ney Disease Outcomes Quality Initiative (K/DOQITM).
Conclusion. The management of disordered calcium and
phosphate homeostasis in CKD patients is evolving based on
our knowledge of the major importance of the calcium sensing
receptor (CASR) in controlling parathyroid gland function and
the potent actions of calcimimetics to target CASR.
The purpose of this presentation is to provide an overview of
the role of the CASR in regulation of parathyroid gland func-
tion, to examine the mechanisms whereby calcimimetics target
the CASR, and to review the clinical trials that support the use
of cinacalcet HCl for the treatment of secondary hyperparathy-
roidism in stage 5 chronic kidney disease (CKD).
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CALCIUM: THE PREDOMINANT REGULATOR
OF PARATHYROID GLAND FUNCTION
Parathyroid hormone (PTH), produced and secreted
by the parathyroid gland, is the primary “calcemic” hor-
mone that has direct actions on the kidney to promote
calcium conservation, and on bone to increase calcium
and phosphate efflux. In addition, PTH stimulates syn-
thesis of 1-alpha hydroxylase in the renal proximal tubule,
thereby increasing 1,25-dihydroxyvitamin D3 production
by the kidneys. In turn, calcitriol (1,25-dihydroxyvitamin
D3) increases gastrointestinal absorption of calcium and
phosphate. The net effect of PTH is to create a positive
calcium balance necessary to maintain calcium levels in
a narrow range and to have a phosphaturic effect to ex-
crete the phosphate that accompanies calcium from the
gastrointestinal tract and bone [1].
Chronic kidney disease results in diminished produc-
tion of calcitriol and decreases in serum calcium levels,
as well as increased serum phosphorus concentrations
due to progressive inability to excrete phosphate. These
abnormalities begin when the glomerular filtration rate
(GFR) is below 60 mL/min/1.73m2. Hypocalcemia, acting
through the G protein-coupled calcium sensing recep-
tor (CASR); low 1,25 (OH)2D3, through its effects on
the vitamin D receptor (VDR); and hyperphosphatemia,
through a putative extracellular phosphate sensor, work
in concert to increase PTH secretion, hyperplasia, and
hypertrophy of the parathyroid glands. The relative roles
of hypocalcemia, hyperphosphatemia, and 1,25 (OH)2D3
deficiency in the genesis of secondary hyperparathy-
roidism are difficult to separate because of the interrela-
tionship among these factors. Although impaired calcium
sensing (altered calcium set point) has been described
in uremic tertiary hyperparathyroidism, the majority of
patients with end-stage renal disease (ESRD) have im-
paired suppression of PTH that correlates with the in-
crease in gland mass instead of impaired calcium sensing
[2].
The molecular targets in the parathyroid gland that
transduce the alterations in systemic homeostasis into
increased PTH production and secretion and parathy-
roid gland growth provide another perspective of the
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Fig. 1. Molecular targets regulating parathy-
roid gland function include, in rank order of
importance, CASR, VDR, and a hypothetical
phosphate sensing mechanism.
Table 1. K/DOQI(TM) clinical practice guidelines for bone metabolism and disease in CKD
Recommended serum values
GFR range Phosphorus Calcium Ca × P Intact PTH
CKD stage mL/min/1.73m2 mg/dL (corrected) mg/dL unit pg/mL
3 30–59 2.7–4.6 8.4–10.2 35–70
4 15–29 2.7–4.6 8.4–10.2 70–110
5 <15, dialysis 3.5–5.5 8.4–9.5 <55 150–300
Modified from National Kidney Foundation K/DOQITM, Am J Kidney Dis 43:S1–S201, 2004.
pathogenesis of secondary hyperparathyroidism. Three
molecular targets have been identified that regulate
parathyroid gland function (Fig. 1). These targets in-
clude CASR, the cell surface G protein-coupled recep-
tor for extracellular calcium [3]; the vitamin D receptor
(VDR), a member of the nuclear receptor family con-
trolling gene transcription [4]; and an uncharacterized
phosphate sensing mechanism [5]. Studies of CASR and
vitamin D receptor (VDR) knockout mice suggest that
CASR is the major regulator of PTH transcription, secre-
tion, and parathyroid gland hyperplasia, whereas VDR,
which affects PTH transcription but not PTH secretion,
may have a subordinate physiologic role to calcium in
regulating parathyroid gland function. In this regard, sec-
ondary hyperparathyroidism and bone abnormalities in
VDR-deficient mice can be corrected by normalizing
serum calcium concentrations, whereas hyperparathy-
roidism in CASR-deficient mice cannot be corrected by
elevated 1,25(OH)2D3. In addition, several clinical tri-
als indicate that calcium administration, in the absence
of concomitant vitamin D therapy, can be as effective
as treatment with either oral or intravenous calcitriol in
reducing PTH levels, but with less hyperphosphatemia
with calcium-only treatment because of the added ability
of calcium to act as a phosphate binder, and a compar-
ative worsening of hyperphosphatemia in the calcitriol-
treated group [6]. This does not mean that 1,25 (OH)2D3
and/or true deficiency of vitamin D [as reflected by low
circulating levels of 25-(OH)] are not important contribu-
tors to parathyroid disease or other vitamin D-dependent
functions. However, vitamin D analogues, particularly
when administered in high doses intravenously, are as-
sociated with increased calcium-phosphorus (Ca × P)
products in patients [6], and can be used to create vas-
cular calcifications in animal models [7]. It also does not
mean that calcium alone, which requires high does to ef-
fectively suppress PTH levels in stage 5 CKD, is with-
out risk. Indeed, prospective comparisons of calcium and
noncalcium phosphate binders indicate that noncalcium-
containing phosphate binders result in less vascular calci-
fication than treatments that include calcium-containing
phosphate binders [8]. In any event, therapies with cal-
cium and vitamin D analogues have limitations that
preclude achieving their maximal benefit in treatment of
secondary hyperparathyroidism in CKD.
GUIDELINES FOR TREATMENT OF
SECONDARY HYPERPARATHYROIDISM
Concerns about the risk of hypercalcemia, hyperphos-
phatemia, vascular calcification, and their contribution
to increased morbidity and mortality in stage 5 CKD in-
fluenced the National Kidney Foundation Kidney Dis-
ease Outcomes Quality Initiative (K/DOQITM) clinical
practice guidelines for bone metabolism and disease [9]
(Table 1). Because the risk of mortality associated with
hyperphosphatemia increases at a serum phosphorus of
>6.2 units, the upper limit for serum phosphorus in
K/DOQI(TM) in stage 5 CKD is 5.5. Also, because of
the risk of calcium loading and hypercalcemia, the rec-
ommendations set a new upper limit of serum calcium at
9.5 mg/dL for stage 5 CKD patients, which is below the
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upper limit of 10.2 in normal individuals. For similar rea-
sons, the Ca × P product is recommended to be main-
tained at values less than 55. The optimal PTH level
by the intact assays is recommended to be between 150
pg/mL and 300 pg/mL (biointact range of 80–160 pg/mL).
In addition to the stringent biochemical requirements,
K/DOQITM also suggested limitations to certain treat-
ments in order to help attain these goals. These restric-
tions include limiting the total dose of calcium-based
phosphate binders to no more than 1500 mg/day, and a to-
tal intake of calcium to less than 2000 mg/day. In addition,
this group suggests that patients with intact PTH >300
pg/mL should be treated with active vitamin D sterols,
but only if serum levels of calcium are <9.5 mg/dL and
phosphorus <5.5 mg/dL.
There are several concerns with the K/DOQITM guide-
lines. First, outcome data are lacking to support the ben-
eficial effect of attaining these biochemical end points.
In particular, the lowering of the upper limit of calcium
lacks adequate support. In addition, calcium absorption
is increased by concomitant vitamin D therapy [6]. Possi-
bly, higher amounts of dietary calcium can be tolerated in
the absence of high-dose vitamin D therapy. In addition,
the potential risks/benefits of vitamin D therapy have not
been quantified. While vitamin D deficiency may have
a negative impact on many organ systems, it is not es-
tablished that the current practice of administering high
doses of intravenous vitamin D analogues is necessary to
treat vitamin D deficiency, or whether this pharmacologic
approach is safe. In addition, achieving the targets with
current treatment regimens may be difficult, with fewer
than 6% of the patients achieving all 4 of the guidelines
[10]. Finally, little attention was given to the efficacy of
the current therapeutic approaches, which utilize vita-
min D therapy, calcium supplementation, and phosphate
binders. The persistent high incidence of refractory hy-
perparathyroidism (the incidence of parathyroidectomy
in patients who started renal replacement therapy be-
tween 1990 and 1992, an era of intensive therapy with
vitamin D analogues, is no different from that observed
in patients who started dialysis between 1983 and 1985)
suggests that the current therapy may not be adequate
to prevent the progression of parathyroid gland hyper-
plasia, which increases as a function of duration of renal
replacement therapy [11].
CALCIMIMETICS: NOVEL ALLOSTERIC
MODULATORS OF THE CALCIUM SENSING
RECEPTOR
CASR, a 7 transmembrane G protein-coupled cell
surface receptor with a large extracellular domain, is a
target for the development of small organic compounds
capable of selectively modifying CASR function and
suppressing PTH. Screening of phenylalkylamine-type
compounds led to the discovery of calcimimetics, which
are allosteric modulators of CASR that increase the
sensitivity of CASR to extracellular calcium. NPS-568 un-
derwent limited clinical studies. Cinacalcet HCl, a second
generation calcimimetic with a chemical structure of (R)-
(–)-a-methyl-N-[3-[3-[trifluoromethylphenyl]propyl]-1-
napthalenemethanamine, has been FDA approved for
the treatment of secondary hyperparathyroidism in stage
5 CKD patients [12]. In vitro studies in cells transfected
with CASR indicate that calcimimetics are ineffective
in the absence of extracellular calcium. However,
they markedly enhance the activation of CASR in the
presence of extracellular calcium. More importantly, ad-
dition of calcimimetics to dispersed bovine parathyroid
cells results in a dose-dependent suppression of PTH
secretion and flattening of the calcium-PTH response
curves, such that PTH secretion is maximally suppressed
even at low calcium concentrations. Additional studies
in animal models of hyperparathyroidism indicate that
cinacalcet HCl can also prevent the development of
parathyroid gland hyperplasia [13].
PHASE II AND III CLINICAL TRIALS WITH
CINACALCET HCl
To date, phase II and III trials have been reported that
support the efficacy and safety of cinacalcet HCl as ad-
juvant treatment of secondary hyperparathyroidism [14,
15]. Both phase II and III trials had similar study de-
signs, in which patients with PTH values >300 pg/mL
participated in a placebo-controlled, double-blind, ran-
domized study consisting of 2 phases: a 12-week dose-
titration phase and a maintenance phase. In both trials,
the control group continued current treatment that could
include calcium supplementation, noncalcium binders,
and vitamin D analogues; the treatment group received
an addition of cinacalcet HCl on top of existing treat-
ment. During the titration phase, which was introduced
to minimize hypocalcemia, cinacalcet HCl was increased
from a starting dose of 25 mg/day or 30 mg/day to a max-
imal dose of 100 mg or 180 mg in the phase II and III
trials, respectively. In the phase III trial, patients were
stratified according to disease severity and baseline val-
ues for the Ca × P product. No restrictions were imposed
on the dose or type of phosphate binder. Increases in the
dose of vitamin D sterols were permitted if parathyroid
hormone levels increased by more than 50%, or if serum
calcium levels were below 8.4 mg/dL. Doses of vitamin D
sterols were reduced if (1) calcium levels exceeded 11.0
mg/dL; (2) phosphorus levels exceeded 6.5 mg/dL; (3) the
Ca × P product exceeded 70 mg2/dL2; or (4) parathyroid
hormone levels were l<100 pg/mL. The phase II trial en-
rolled 71 patients from 17 centers in the United States,
and the phase III trial enrolled 741 (410 in North America
and 331 in Europe and Australia). For the phase II trial,
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Fig. 2. Changes in serum PTH, calcium, phosphorus, and Ca × P prod-
uct in placebo- and cinacalcet HCl (AMG073)-treated patients enrolled
in a phase II trial. Reprinted with permission from Lippincott Williams
& Wilkins.
the dose of cinacalcet HCl or placebo was increased until
patients had achieved both a reduction in PTH of =30%
from baseline and an absolute PTH ≥250 pg/mL, and for
the phase III trial, increases in the dose were permitted if
parathyroid hormone levels remained above 200 pg/mL
and serum calcium levels were at least 7.8 mg/dL.
The results of the phase II (Fig. 2) and III (Fig. 3) tri-
als are similar. Efficacy, assessed using PTH values ob-
tained at the end of the dosing interval (i.e., 24 hours
after the previous dose of study drug), decreased progres-
sively during the dose-titration phase, and the reduction
was sustained throughout the maintenance phase. Mini-
mal change from baseline was observed in the placebo
groups. During the maintenance phase, PTH concen-
trations in the cinacalcet group were reduced by 33%
24 hours after dosing (Fig. 2) compared with an increase
of 3% in the placebo group (P < 0.001). In the phase III
trial, mean parathyroid hormone levels were 43% lower
than baseline in patients receiving cinacalcet, but 9%
higher in those receiving placebo (P < 0.001) (Fig. 3). This
reduction underestimates the maximal reduction, which
is typically observed 4 hours after the dose of cinacal-
cet HCl. Mean serum calcium decreased in the cinacalcet
group by 4.6% to 6.8%. Treatment with cinacalcet was
associated with reduction of phosphorus levels, averag-
ing 8.4% in the phase III trial. Values for calcium and
phosphorus were not significantly changed in the placebo
group. Changes in PTH and Ca × P product were not ex-
plained by adjustments in concomitant therapy. Values
for the Ca × P product decreased by 7.9% and 14.6%
in the cinacalcet HCl groups in the phase I and II stud-
ies, respectively, but were not decreased in the placebo
group. Thus, treatment with cinacalcet HCl caused signif-
icant decreases in PTH without elevating serum calcium
or phosphorus.
Cinacalcet HCl appeared to be well tolerated. Asymp-
tomatic hypocalemia and nausea were the most frequent
complications observed in the cinacalcet-treated groups.
Finally, the use of cinacalcet HCl resulted in approxi-
mately 41% of patients attaining PTH and Ca × P values
recommended by the K/DOQITM guidelines compared
with less than 10% achieving optimal control in the group
treated with phosphate binders and vitamin D analogues
alone.
TREATMENT PARADIGMS FOR SECONDARY
HYPERPARATHYROIDISM IN STAGE 5 CKD
Cinacalcet HCl provides one more ingredient to add
to the possible drug recipes for treating secondary hy-
perparathyroidism in stage 5 CKD. Prior to the introduc-
tion of this calcimimetic, our “best” therapy consisted
of the combination of active vitamin D analogues, ele-
mental calcium supplementation (1.5 g/day), and non-
calcium/nonaluminum phosphate binders. The available
clinical trials show that the addition of cinacalcet HCl to
the current “best” therapy results in better biochemical
control. Such adjuvant use of cinacalcet HCl is likely to
become the standard of care.
It is also possible that cinacalcet HCl might be used to
reduce the amount of vitamin D analogues needed to
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Fig. 3. Mean (±SEM) plasma parathyroid hormone levels as a func-
tion of time in the combined phase III trials comparing placebo with
cinacalcet HCl treatment in stage 5 CKD patients. Reprinted with per-
mission from Massachusetts Medical Society.
suppress PTH, and to permit the use of calcium-
containing phosphate binder in doses >1.5 g/day. In this
regard, a subgroup of patients in the phase II and III
trails received no vitamin D administration; analysis of
this subgroup demonstrated that cinacalcet HCl was also
effective in the absence of concomitant vitamin D therapy
[14, 15].
Given the importance of CASR in regulating parathy-
roid function and the current side effects of combined
therapy with calcium and high dose vitamin D to increase
the Ca × P product, calcimimetics offer the promise of an
effective and safer treatment of secondary hyperparathy-
roidism in stage 5 CKD. Additional studies, however, are
needed to evaluate the effect of cinacalcet HCl in altering
the natural history of hyperparathyroid disease, and the
impact of lowering the Ca × P product with this drug on
subsequent vascular calcifications. Studies are needed, as
well, to evaluate the effect of these changes in treatment
on the development and progression of the various forms
of renal osteodystrophy.
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